Canada markets close in 3 hours 32 minutes

AstraZeneca PLC (AZN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
64.82-1.12 (-1.71%)
As of 12:28PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous Close65.95
Open64.73
Bid64.68 x 800
Ask64.68 x 900
Day's Range64.57 - 65.38
52 Week Range53.63 - 71.70
Volume6,571,533
Avg. Volume7,020,868
Market Cap200.89B
Beta (5Y Monthly)0.12
PE Ratio (TTM)N/A
EPS (TTM)-0.36
Earnings DateN/A
Forward Dividend & Yield1.44 (2.17%)
Ex-Dividend DateFeb 24, 2022
1y Target Est71.80
  • Zacks

    AstraZeneca (AZN) to Buy TeneoTwo, Boost Hematology Pipeline

    AstraZeneca's (AZN) acquisition of TeneoTwo is set to add an early-stage T-cell engager to AZN's pipeline. The transaction is likely to close by third-quarter 2022.

  • Reuters

    UPDATE 2-AstraZeneca to buy biotech firm TeneoTwo for up to $1.27 bln

    AstraZeneca agreed to acquire biotechnology firm TeneoTwo Inc in a deal worth up to $1.27 billion on Tuesday, in a move to bolster its roster of therapies to treat blood cancers. At the heart of the deal is the U.S.-based company's early stage experimental treatment for a form of Non-Hodgkin's lymphoma, a type of cancer that involves the growth of abnormal white blood cells that can lead to the emergence of tumours. The Anglo-Swedish drugmaker - whose key blood cancer drug Calquence generated sales of more than $1.2 billion last year - plans to acquire all outstanding equity of TeneoTwo for an upfront payment of $100 million, with additional milestone-related payments of up to $1.17 billion.